ATE556719T1 - Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält - Google Patents

Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Info

Publication number
ATE556719T1
ATE556719T1 AT10003160T AT10003160T ATE556719T1 AT E556719 T1 ATE556719 T1 AT E556719T1 AT 10003160 T AT10003160 T AT 10003160T AT 10003160 T AT10003160 T AT 10003160T AT E556719 T1 ATE556719 T1 AT E556719T1
Authority
AT
Austria
Prior art keywords
influenza
epitopes
human
peptides
epitope
Prior art date
Application number
AT10003160T
Other languages
German (de)
English (en)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Raphael Levi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE556719T1 publication Critical patent/ATE556719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT10003160T 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält ATE556719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
ATE556719T1 true ATE556719T1 (de) 2012-05-15

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10003160T ATE556719T1 (de) 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Country Status (15)

Country Link
US (3) US6740325B1 (enExample)
EP (2) EP1135159A2 (enExample)
JP (1) JP2002531415A (enExample)
KR (1) KR100703571B1 (enExample)
AT (1) ATE556719T1 (enExample)
AU (1) AU766883B2 (enExample)
BR (1) BR9915811A (enExample)
CA (1) CA2352454C (enExample)
DK (1) DK2204187T3 (enExample)
ES (1) ES2389611T3 (enExample)
HK (1) HK1040620A1 (enExample)
IL (3) IL127331A0 (enExample)
NZ (1) NZ511918A (enExample)
PT (1) PT2204187E (enExample)
WO (1) WO2000032228A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
DK1692265T3 (da) 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2007051036A2 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
AU2006322907B2 (en) * 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
HUE049580T2 (hu) * 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2534332T3 (es) * 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2139908A4 (en) 2007-03-12 2011-02-16 Antigen Express Inc REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
JP5654345B2 (ja) 2007-08-02 2015-01-14 ビオンドヴァックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザワクチン
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
WO2013028738A1 (en) 2011-08-22 2013-02-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
EP3662927A3 (en) 2013-02-05 2020-10-21 Nitto Denko Corporation Vaccine composition
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
RU2014102948A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для мукозального введения
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
CA2841016A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
US20140220100A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
EP3189852B1 (en) 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition
WO2018126060A1 (en) * 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
EP1135159A2 (en) 2001-09-26
KR100703571B1 (ko) 2007-04-05
EP2204187A1 (en) 2010-07-07
IL143367A0 (en) 2002-04-21
US6740325B1 (en) 2004-05-25
US20050002954A1 (en) 2005-01-06
CA2352454A1 (en) 2000-06-08
HK1040620A1 (zh) 2002-06-21
WO2000032228A3 (en) 2000-10-05
DK2204187T3 (da) 2012-08-20
JP2002531415A (ja) 2002-09-24
CA2352454C (en) 2013-02-05
IL127331A0 (en) 1999-09-22
US7192595B2 (en) 2007-03-20
BR9915811A (pt) 2001-08-21
US20070122424A1 (en) 2007-05-31
NZ511918A (en) 2003-08-29
AU766883B2 (en) 2003-10-23
EP2204187B1 (en) 2012-05-09
AU1406600A (en) 2000-06-19
IL143367A (en) 2006-09-05
US7514086B2 (en) 2009-04-07
HK1145448A1 (en) 2011-04-21
ES2389611T3 (es) 2012-10-29
KR20010089512A (ko) 2001-10-06
PT2204187E (pt) 2012-08-10
WO2000032228A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
ATE556719T1 (de) Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält
JP2002531415A5 (enExample)
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ES2060603T3 (es) El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
Stryhn et al. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
TW200505943A (en) Polypeptide
DE69110891D1 (de) Peptide und analoge und mischungen davon zum nachweis der gegen die viren htlv-1 und htlv-ii gerichteten antikörper.
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
Cole et al. T cell recognition of the immunodominant Sendai virus NP324-332/Kb epitope is focused on the center of the peptide
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
RU2001113277A (ru) Регуляторные/развернутые пептиды эзрина